Michael Barbella, Managing Editor12.16.22
Nova Biomedical has received U.S. Food and Drug Administration (FDA) clearance for the Nova Primary as a blood glucose reference analyzer. Nova Primary fills the need for a new glucose reference analyzer to replace the discontinued YSI STAT PLUS 2300 Glucose and L-Lactate analyzer.
Blood glucose measuring device manufacturers and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need. With the FDA clearance, Nova Primary is now available in the United States and worldwide. “We at Nova Biomedical are pleased to offer the Nova Primary, an accurate, easy-to-use and modernized blood glucose reference analyzer for glucose device manufacturers and clinical diabetes researchers to replace the discontinued YSI Stat Plus glucose analyzer,” Nova Sales Product Line Manager Matthew McRae said.
Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25 microliter venous whole blood or plasma sample which is internally diluted as in the YSI. Results are available in approximately two minutes. Nova Primary’s large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma, the Nova Primary demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards. The Nova Primary uses a comma delimited (.csv) format data output that can be downloaded via the integral USB data port. The analyzer measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).
Incorporated in 1976 and based in Waltham, Mass., Nova Biomedical develops and manufactures whole blood, point-of-care, and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of more than 22 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing more than 20 critical cell culture tests for a broad range of cell culture applications. Nova employs more than 1,400 people worldwide and has wholly owned subsidiaries located in Benelux, Brazil, Canada, France, Germany, Great Britain, Italy, Japan Spain, and Switzerland. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the United States and Taiwan.
Blood glucose measuring device manufacturers and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need. With the FDA clearance, Nova Primary is now available in the United States and worldwide. “We at Nova Biomedical are pleased to offer the Nova Primary, an accurate, easy-to-use and modernized blood glucose reference analyzer for glucose device manufacturers and clinical diabetes researchers to replace the discontinued YSI Stat Plus glucose analyzer,” Nova Sales Product Line Manager Matthew McRae said.
Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25 microliter venous whole blood or plasma sample which is internally diluted as in the YSI. Results are available in approximately two minutes. Nova Primary’s large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma, the Nova Primary demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards. The Nova Primary uses a comma delimited (.csv) format data output that can be downloaded via the integral USB data port. The analyzer measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).
Incorporated in 1976 and based in Waltham, Mass., Nova Biomedical develops and manufactures whole blood, point-of-care, and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of more than 22 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing more than 20 critical cell culture tests for a broad range of cell culture applications. Nova employs more than 1,400 people worldwide and has wholly owned subsidiaries located in Benelux, Brazil, Canada, France, Germany, Great Britain, Italy, Japan Spain, and Switzerland. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the United States and Taiwan.